GLP-1s and Your Teeth: Uncovering the Surprising Dental Impact

Last Updated: OCTOBER 2024

The rise of GLP-1 receptor agonists has fundamentally reshaped the landscape of metabolic health, offering unprecedented efficacy for weight loss and glycemic control. With 42.4% of US adults classified as obese by the CDC's 2022 data, these medications, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), represent a critical therapeutic advancement. Yet, as millions embrace these powerful drugs, an unexpected and often overlooked consequence is emerging in dental clinics nationwide: a concerning pattern of oral health deterioration, colloquially dubbed "Ozempic teeth." This isn't a direct pharmacological assault on enamel, but rather a cascading effect of common gastrointestinal side effects that, if unmanaged, can inflict significant and lasting damage to teeth and gums.

The term "Ozempic teeth" itself isn't a formal medical diagnosis, but it encapsulates a growing collection of observations from dental professionals seeing an uptick in specific oral health issues among patients prescribed GLP-1 medications. This phenomenon highlights a critical gap in holistic patient care, where the focus on metabolic improvement often overshadows the potential for downstream effects on other vital body systems, particularly the oral cavity. For patients, understanding these risks and proactively managing them is paramount to preserving long-term dental health while reaping the systemic benefits of these innovative treatments.

The Corrosive Threat: Enamel Erosion

The primary concern linking GLP-1 drugs to dental issues stems from their well-documented gastrointestinal side effects. Nausea, vomiting, and gastroesophageal reflux disease (GERD) are among the most frequently reported adverse events, particularly during the initial dose titration phase. Clinical trial data for semaglutide (Ozempic) shows nausea impacting 20% to 44% of users, with vomiting reported in 9% to 24.2% of participants, depending on the dosage and study arm (Novo Nordisk, Ozempic Prescribing Information, 2024). Tirzepatide (Mounjaro) exhibits similar rates, with nausea affecting 23.3% to 26.5% and vomiting 6.4% to 9.2% of users at therapeutic doses (Eli Lilly, Mounjaro Prescribing Information, 2024).

Repeated exposure to stomach acid, whether through acute vomiting episodes or chronic acid reflux, is profoundly detrimental to tooth enamel. Enamel, the hardest substance in the human body, is highly susceptible to acid demineralization. Each time stomach acid washes over the teeth, it softens the enamel, making it more vulnerable to wear, abrasion from brushing, and erosion. Over time, this process leads to irreversible enamel loss, which can manifest as increased tooth sensitivity, discoloration, changes in tooth shape, and a heightened risk of dental caries (cavities).

The mechanism is starkly similar to the dental erosion observed in individuals with bulimia nervosa, where frequent self-induced vomiting leads to characteristic patterns of enamel loss, particularly on the lingual (tongue-facing) surfaces of anterior teeth. While GLP-1 users rarely experience the frequency of vomiting seen in eating disorders, even intermittent exposure over months or years can accumulate substantial damage. This gradual, insidious erosion often goes unnoticed by patients until significant sensitivity or visible tooth degradation prompts a dental visit.

The Dry Mouth Dilemma: Xerostomia and its Consequences

Beyond acid exposure, another significant contributor to GLP-1-associated dental problems is xerostomia, or dry mouth. While not always listed as a primary side effect, many patients report reduced saliva flow. Saliva plays a crucial protective role in oral health. It neutralizes acids, washes away food debris, and contains minerals like calcium and phosphate that help remineralize enamel, counteracting early demineralization. A sustained reduction in saliva dramatically compromises these natural defenses.

When saliva flow is diminished, the mouth becomes a more hospitable environment for pathogenic bacteria. The natural buffering capacity is lost, leading to a more acidic oral pH, which accelerates enamel dissolution. Patients with chronic dry mouth frequently experience:

• Increased rates of dental caries: Especially at the gumline and on root surfaces, as these areas are typically protected by saliva.
• Gum inflammation (gingivitis) and periodontal disease: Reduced salivary cleansing allows plaque to accumulate more readily.
• Oral discomfort: Burning sensations, difficulty speaking or swallowing, and altered taste perception.
• Fungal infections: Such as oral candidiasis, due to altered oral flora.

For individuals already at higher risk for oral health issues due to underlying metabolic conditions like diabetes, where compromised immune function and higher blood sugar can independently increase susceptibility to gum disease and infections, dry mouth from GLP-1s adds another layer of vulnerability. The synergy of reduced saliva and acid exposure creates a perfect storm for rapid dental deterioration.

An Ounce of Prevention: Dental Care Recommendations

The emergence of "Ozempic teeth" underscores the urgent need for a coordinated, multidisciplinary approach to patient care. Prescribing physicians, while focused on metabolic outcomes, must integrate oral health into their patient assessments and counseling. Similarly, dental professionals need to be aware of their patients' medication regimens and screen for specific GLP-1-related oral health concerns.

The FDA, in its general guidance on medication side effects, notes, "Patients should report any new or worsening symptoms to their healthcare provider. Proactive management of side effects can significantly improve patient safety and medication adherence." This extends directly to oral health; patients are not always aware that stomach issues can directly harm their teeth.

For patients currently on GLP-1 medications or considering them, several proactive measures can significantly mitigate the risks:

• Communicate with your dental team: Inform your dentist and hygienist about all medications you are taking, especially GLP-1s, so they can tailor preventive strategies.
• Aggressive acid management: If experiencing nausea, vomiting, or GERD, discuss strategies with your prescribing physician. This might include adjusting medication timing, dose, or co-prescribing antacids. After an acute vomiting episode, rinse your mouth immediately with plain water or a fluoride mouthwash; avoid brushing for at least 30 minutes to an hour, as enamel is softened and more prone to abrasion.
• Prioritize hydration: Combat dry mouth by drinking plenty of water throughout the day. Sugar-free gum or lozenges can stimulate saliva production. Over-the-counter artificial saliva products can also provide relief.
• Enhanced fluoride exposure: Use a high-fluoride toothpaste daily, and consider a fluoride mouthwash. Your dentist may also recommend in-office fluoride varnish applications or prescription-strength fluoride products to strengthen enamel and prevent demineralization.
• Maintain meticulous oral hygiene: Brush twice daily with a soft-bristle toothbrush and fluoride toothpaste. Floss daily to remove plaque and food debris from between teeth.
• Regular dental check-ups